ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Arcutis to Report Third Quarter 2023 Financial Results

25 Oct 2023 15:00:00 By Nasdaq GlobeNewswire

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

20 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Pricing of $100 Million Public Offering

19 Oct 2023 22:45:47 By Nasdaq GlobeNewswire

Arcutis Announces Proposed Public Offering

19 Oct 2023 15:04:44 By Nasdaq GlobeNewswire

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

13 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

06 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Oct 2023 15:00:00 By Nasdaq GlobeNewswire

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

27 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

25 Sep 2023 08:00:47 By Nasdaq GlobeNewswire

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

19 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Sep 2023 15:00:00 By Nasdaq GlobeNewswire

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

12 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

07 Sep 2023 07:15:50 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

05 Sep 2023 15:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%  

29 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Arcutis Appoints Interim Chief Financial Officer (CFO)

18 Aug 2023 15:30:00 By Nasdaq GlobeNewswire

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

10 Aug 2023 07:16:31 By Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

08 Aug 2023 15:02:00 By Nasdaq GlobeNewswire